| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 0 | 25 | 80* | - |
| Research and development | 1,345 | 1,297 | 1,315* | 1,203 |
| Impairment of intangible assets | - | - | 0* | 0 |
| General and administrative | 1,326 | 1,416 | 1,393* | 1,315 |
| Total operating expenses | 2,671 | 2,713 | 2,708* | 2,518 |
| Loss from operations | -2,671 | -2,688 | -2,628* | -2,518 |
| Interest income | 217 | 163 | 165* | 187 |
| Interest expense | 719 | 229 | 82* | 57 |
| Foreign exchange losss (gaines) | -104 | 4 | -997* | -418 |
| Change in fair value of derivative and warrant liabilities | 128 | 0 | -1* | 0 |
| Total other income (expense), net | -734 | -62 | -913* | -288 |
| Loss before income tax expense (benefit) | - | - | -3,542* | -2,806 |
| Income tax expense (benefit) | - | - | 0* | 0 |
| Net loss | -3,405 | -2,800 | -3,542* | -2,806 |
| Gain on extinguishment of series a convertible preferred stock-Series AConvertible Preferred Stock | - | - | - | 0 |
| Deemed dividends on preferred stock-Series APreferred Stock | - | - | 0* | 0 |
| Deemed dividends on preferred stock-Redeemable Series AConvertible Preferred Stock | - | - | 0* | - |
| Deemed dividend on preferred stock-Series AConvertible Preferred Stock | - | - | - | 0 |
| Gain on extinguishment of series a preferred stock-Series APreferred Stock | - | - | 0* | - |
| Change in cumulative translation adjustment | -267 | -100 | - | - |
| Net loss attributable to common stockholders | - | - | -3,542 | -2,806 |
| Total comprehensive loss | -3,672 | -2,808 | - | - |
| Basic EPS | -0.21 | -0.17 | -0.276 | -0.19 |
| Basic Average Shares | 15,910,724 | 15,968,591 | 12,853,705 | 14,739,800 |
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)